Storia in 2 fonti

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

The FDA has expanded the label for Pfizer’s subcutaneous hemop | The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the treatment to those 12 and older who have developed inhibitors.

Raccontata da

healio.com

fiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo4 g fa

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

originale

healio.com4 g fa

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

The FDA has expanded approval for marstacimab-hncq, which can now be given as routine prophylaxis for all individuals aged 6 years and older with hemophilia A or B, with or without inhibitors, Pfizer announced in a…

Leggi questa versione → originale

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

Confronto fonti

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Timeline cronologica

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

Confronto fonti

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Timeline cronologica

FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi